SCHEMBL4876755

SCHEMBL4876755

COc1cccc(C2(C(=O)NS(=O)(=O)N(C)Cc3ccccc3)CCN(c3ncccn3)CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 6/20 0.44
KCNH2 Q12809 1/20 0.44
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
TACR3 P29371 1/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
CHRM5 P08912 2/20 0.39
CHRM3 P20309 2/20 0.39
CHRM1 P11229 1/20 0.39
OPRK1 P41145 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4873475 0.87 ALDH1A1 (0.43) OPRD1KCNH2ALDH1A1KDM4EGAA
SCHEMBL4878695 0.85 OPRD1 (0.49) OPRD1KCNH2ALDH1A1KDM4EGAA
SCHEMBL4876692 0.83 ALDH1A1 (0.49) OPRD1KCNH2ALDH1A1KDM4EGAA
SCHEMBL5480789 0.82 OPRD1 (0.62) OPRD1KCNH2ALDH1A1KDM4EGAA
SCHEMBL4868393 0.82 ALDH1A1 (0.48) OPRD1KCNH2ALDH1A1KDM4EGAA
SCHEMBL4876648 0.81 ALDH1A1 (0.47) OPRD1KCNH2ALDH1A1KDM4EGAA
SCHEMBL4876628 0.81 ALDH1A1 (0.47) OPRD1KCNH2ALDH1A1KDM4EGAA
SCHEMBL4872054 0.79 ALDH1A1 (0.44) OPRD1KCNH2ALDH1A1KDM4EHPGD
SCHEMBL5487731 0.79 ALDH1A1 (0.53) OPRD1KCNH2ALDH1A1KDM4EGAA
SCHEMBL4877181 0.78 ALDH1A1 (0.56) ALDH1A1KDM4EGAAHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096922-A1 Novel Sulfonamide derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-04-24 US disclosed
EP-1736467-A1 NOVEL SULFONAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096922-A1 Novel Sulfonamide derivative NR4A1, NR4A2, NR4A3 OPRD1 628/4885KCNH2 3037/4885ALDH1A1 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.